Human interleukin-12α and EBI3 are cytokines with anti-inflammatory functions.

Détails

ID Serval
serval:BIB_67C40EE6710B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Human interleukin-12α and EBI3 are cytokines with anti-inflammatory functions.
Périodique
Science advances
Auteur⸱e⸱s
Hildenbrand K., Bohnacker S., Menon P.R., Kerle A., Prodjinotho U.F., Hartung F., Strasser P.C., Catici DAM, Rührnößl F., Haslbeck M., Schumann K., Müller S.I., da Costa C.P., Esser-von Bieren J., Feige M.J.
ISSN
2375-2548 (Electronic)
ISSN-L
2375-2548
Statut éditorial
Publié
Date de publication
27/10/2023
Peer-reviewed
Oui
Volume
9
Numéro
43
Pages
eadg6874
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Interleukins are secreted proteins that regulate immune responses. Among these, the interleukin 12 (IL-12) family holds a central position in inflammatory and infectious diseases. Each family member consists of an α and a β subunit that together form a composite cytokine. Within the IL-12 family, IL-35 remains particularly ill-characterized on a molecular level despite its key role in autoimmune diseases and cancer. Here we show that both IL-35 subunits, IL-12α and EBI3, mutually promote their secretion from cells but are not necessarily secreted as a heterodimer. Our data demonstrate that IL-12α and EBI3 are stable proteins in isolation that act as anti-inflammatory molecules. Both reduce secretion of proinflammatory cytokines and induce the development of regulatory T cells. Together, our study reveals IL-12α and EBI3, the subunits of IL-35, to be functionally active anti-inflammatory immune molecules on their own. This extends our understanding of the human cytokine repertoire as a basis for immunotherapeutic approaches.
Mots-clé
Humans, Cytokines/metabolism, Interleukin-12/metabolism, Interleukins/metabolism, Minor Histocompatibility Antigens/metabolism, T-Lymphocytes, Regulatory
Pubmed
Open Access
Oui
Création de la notice
26/10/2023 14:59
Dernière modification de la notice
19/12/2023 8:15
Données d'usage